{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:34:39Z","timestamp":1790015679711,"version":"4.0.1"},"reference-count":44,"publisher":"Bioscientifica","issue":"5","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":301,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Medullary thyroid carcinoma (MTC) is a rare neuroendocrine thyroid tumor, with only 30 new patients annually in the Netherlands. PET imaging provides information on distant metastases, after which tyrosine kinase inhibitors (TKIs) may be initiated. The rarity of the disease impedes large controlled trials, and therefore the challenge of selecting the best TKI and PET tracer for individual patients persists. To explore whether an in vitro model could be developed to guide the selection of appropriate PET tracers or TKI therapies in the future, we aimed to establish an MTC organoid model for the first time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Dispersed cells from MTC biopsies were suspended in Matrigel, allowing organoid formation. The self-renewal potential was tested by dissociation and re-plating cells and determining organoid-forming efficiency. MTC-specific gene and protein expression were characterized by qPCR and immunofluorescent staining. Moreover, MTC-organoids (MTOs) were exposed to TKIs and PET tracers in proof-of-principle experiments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten MTC biopsies were processed and successfully cultured as MTOs. MTC-derived cells showed self-renewal potency for several passages, indicating the presence of putative stem cells. Gene and protein expression of MTC-specific markers in tissue and MTOs, and function measurements showed the production of calcitonin and CEA. Interpretation of the preliminary experiments with TKIs and PET tracers was limited by sample size but demonstrates their future potential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We were able to culture MTC organoids that resemble the original tissue in gene expression, protein expression, and functionality. However, international, multi-center studies are required to meet the standards for future clinical applications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-24-0405","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T12:26:53Z","timestamp":1755520013000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":4,"title":["Patient-derived medullary thyroid cancer organoids: a potential model for mechanistic studies on diagnostics and therapy"],"prefix":"10.1530","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8296-6703","authenticated-orcid":true,"given":"Eline C","family":"Jager","sequence":"first","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3798-9393","authenticated-orcid":true,"given":"Luc H J","family":"Sondorp","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufina","family":"Maturi","sequence":"additional","affiliation":[{"name":"3"},{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas F","family":"Antunes","sequence":"additional","affiliation":[{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettien M","family":"van Hemel","sequence":"additional","affiliation":[{"name":"6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uilke","family":"Brouwer","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"Jansen","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter T","family":"Zandee","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne H","family":"Brouwers","sequence":"additional","affiliation":[{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5327-1718","authenticated-orcid":true,"given":"Thera P","family":"Links","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob P","family":"Coppes","sequence":"additional","affiliation":[{"name":"3"},{"name":"7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5151-7320","authenticated-orcid":true,"given":"Schelto","family":"Kruijff","sequence":"additional","affiliation":[{"name":"1"},{"name":"5"},{"name":"8"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"2026070714014424200_bib1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/jcp.19.2.114","article-title":"Histogenesis of medullary carcinoma of the thyroid","volume":"19","author":"Williams","year":"1966","journal-title":"J Clin Pathol"},{"key":"2026070714014424200_bib2","volume-title":"Cancer incidence in five continents-","author":"Curado","year":"2007"},{"key":"2026070714014424200_bib3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00268-017-4321-z","article-title":"Long-term outcome after surgery for medullary thyroid carcinoma: a single-center experience","volume":"42","author":"Torresan","year":"2018","journal-title":"World J Surg"},{"key":"2026070714014424200_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1089\/thy.2014.0277","article-title":"Response to initial therapy predicts clinical outcomes in medullary thyroid cancer","volume":"25","author":"Lindsey","year":"2015","journal-title":"Thyroid"},{"key":"2026070714014424200_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/367375a0","article-title":"A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma","volume":"367","author":"Hofstra","year":"1994","journal-title":"Nature"},{"key":"2026070714014424200_bib6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/363458a0","article-title":"Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A","volume":"363","author":"Mulligan","year":"1993","journal-title":"Nature"},{"key":"2026070714014424200_bib7","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.bjc.6605056","article-title":"Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas","volume":"100","author":"Moura","year":"2009","journal-title":"Br J Cancer"},{"key":"2026070714014424200_bib8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2159-8290.CD-19-1116","article-title":"Advances in targeting RET-dependent cancers","volume":"10","author":"Subbiah","year":"2020","journal-title":"Cancer Discov"},{"key":"2026070714014424200_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CCO.0000000000000798","article-title":"State of the art and future directions in the systemic treatment of medullary thyroid cancer","volume":"34","author":"Jager","year":"2022","journal-title":"Curr Opin Oncol"},{"key":"2026070714014424200_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026070714014424200_bib11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"2026070714014424200_bib12","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.2967\/jnumed.112.105940","article-title":"Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma","volume":"53","author":"Verbeek","year":"2012","journal-title":"J Nucl Med"},{"key":"2026070714014424200_bib13","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00330-008-1280-7","article-title":"The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT","volume":"19","author":"Beheshti","year":"2009","journal-title":"Eur Radiol"},{"key":"2026070714014424200_bib14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ejso.2010.01.001","article-title":"Dual PET\/CT with 18F-DOPA and 18F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging","volume":"36","author":"Marzola","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"2026070714014424200_bib15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00259-011-2031-6","article-title":"Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET\/CT in patients with recurrent medullary thyroid carcinoma","volume":"39","author":"Treglia","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070714014424200_bib16","doi-asserted-by":"crossref","first-page":"524","DOI":"10.2967\/jnumed.107.047720","article-title":"18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation","volume":"49","author":"Koopmans","year":"2008","journal-title":"J Nucl Med"},{"key":"2026070714014424200_bib17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2967\/jnumed.106.036681","article-title":"Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels","volume":"48","author":"Ong","year":"2007","journal-title":"J Nucl Med"},{"key":"2026070714014424200_bib18","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-24-0089","article-title":"The role of [18F]F-DOPA PET\/CT in diagnostic and prognostic assessment of medullary thyroid cancer: a 15-year experience with 109 patients","volume":"13","author":"Zhang","year":"2024","journal-title":"Eur Thyroid J"},{"key":"2026070714014424200_bib19","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s12149-021-01627-2","article-title":"Evaluation of F-18 DOPA PET\/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET\/CT","volume":"35","author":"Asa","year":"2021","journal-title":"Ann Nucl Med"},{"key":"2026070714014424200_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/ijms21010010","article-title":"Multikinase inhibitor treatment in thyroid cancer","volume":"21","author":"Ancker","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026070714014424200_bib21","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070714014424200_bib22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070714014424200_bib23","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","article-title":"Modeling development and disease with organoids","volume":"165","author":"Clevers","year":"2016","journal-title":"Cell"},{"key":"2026070714014424200_bib24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","article-title":"Organoids in cancer research","volume":"18","author":"Drost","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"2026070714014424200_bib25","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.3390\/cancers12113212","article-title":"Patient-derived papillary thyroid cancer organoids for radioactive iodine refractory screening","volume":"12","author":"Sondorp","year":"2020","journal-title":"Cancers"},{"key":"2026070714014424200_bib26","doi-asserted-by":"crossref","first-page":"641980","DOI":"10.3389\/fonc.2021.641980","article-title":"Patient-derived cancer organoids as predictors of treatment response","volume":"11","author":"Verduin","year":"2021","journal-title":"Front Oncol"},{"key":"2026070714014424200_bib27","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.stemcr.2022.09.015","article-title":"Patient-derived parathyroid organoids as a tracer and drug-screening application model","volume":"17","author":"Noltes","year":"2022","journal-title":"Stem Cell Rep"},{"key":"2026070714014424200_bib28","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0046-8177(00)80255-5","article-title":"Expression of thyroid transcription factor-1 (TTF-I) in human C cells and medullary thyroid carcinomas","volume":"31","author":"Katoh","year":"2000","journal-title":"Hum Pathol"},{"key":"2026070714014424200_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026070714014424200_bib30","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/RLU.0000000000002559","article-title":"Thyroid incidentaloma on 18F-fluorocholine PET\/CT and 68Ga-PSMA PET\/CT revealing a medullary thyroid carcinoma","volume":"44","author":"Ciappuccini","year":"2019","journal-title":"Clin Nucl Med"},{"key":"2026070714014424200_bib31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/RLU.0000000000002010","article-title":"Recurrent medullary thyroid carcinoma on 68Ga-Prostate-Specific membrane antigen PET\/CT: exploring new theranostic avenues","volume":"43","author":"Arora","year":"2018","journal-title":"Clin Nucl Med"},{"key":"2026070714014424200_bib32","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/a-1896-0106","article-title":"Medullary thyroid carcinoma presenting as an incidentaloma on gallium-68-PSMA-PET\/CT \u2013 systematic literature review and case report","volume":"61","author":"Eilsberger","year":"2022","journal-title":"Nuklearmedizin"},{"key":"2026070714014424200_bib33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0969-8051(97)00226-6","article-title":"FDG accumulation and tumor biology","volume":"25","author":"Pauwels","year":"1998","journal-title":"Nucl Med Biol"},{"key":"2026070714014424200_bib34","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.2967\/jnumed.109.065664","article-title":"18F-FDOPA: a multiple-target molecule","volume":"50","author":"Minn","year":"2009","journal-title":"J Nucl Med"},{"key":"2026070714014424200_bib35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.humpath.2018.06.035","article-title":"The theranostic target prostate-specific membrane antigen is expressed in medullary thyroid cancer","volume":"81","author":"Lodewijk","year":"2018","journal-title":"Hum Pathol"},{"key":"2026070714014424200_bib36","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1002\/cncr.28858","article-title":"Medical management of metastatic medullary thyroid cancer","volume":"120","author":"Maxwell","year":"2014","journal-title":"Cancer"},{"key":"2026070714014424200_bib37","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41580-020-0259-3","article-title":"Human organoids: model systems for human biology and medicine","volume":"21","author":"Kim","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026070714014424200_bib38","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s12551-019-00590-7","article-title":"Mechanobiology of cells and cell systems, such as organoids","volume":"11","author":"Bayir","year":"2019","journal-title":"Biophys Rev"},{"key":"2026070714014424200_bib39","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.stemcr.2021.02.011","article-title":"Generation and differentiation of adult tissue-derived human thyroid organoids","volume":"16","author":"Ogundipe","year":"2021","journal-title":"Stem Cell Rep"},{"key":"2026070714014424200_bib40","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2117017118","article-title":"Adult mouse and human organoids derived from thyroid follicular cells and modeling of Graves\u2019 hyperthyroidism","volume":"118","author":"van der Vaart","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070714014424200_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s43586-022-00174-y","article-title":"Organoids","volume":"2","author":"Zhao","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"2026070714014424200_bib42","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqad136","article-title":"Progress toward and challenges remaining for thyroid tissue regeneration","volume":"164","author":"Romitti","year":"2023","journal-title":"Endocrinology"},{"key":"2026070714014424200_bib43","doi-asserted-by":"crossref","first-page":"24090","DOI":"10.1074\/jbc.C600122200","article-title":"Sall4 interacts with nanog and co-occupies nanog genomic sites in embryonic stem cells","volume":"281","author":"Wu","year":"2006","journal-title":"J Biol Chem"},{"key":"2026070714014424200_bib44","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/annonc\/mdt177","article-title":"Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy","volume":"24","author":"Kurzrock","year":"2013","journal-title":"Ann Oncol"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/14\/5\/ETJ-24-0405.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/14\/5\/ETJ-24-0405.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-24-0405\/506784\/etj-24-0405.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-24-0405\/506784\/etj-24-0405.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:01:55Z","timestamp":1783447315000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/14\/5\/e240405\/75667\/Patient-derived-medullary-thyroid-cancer-organoids"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-24-0405","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"article-number":"e240405"}}